Supported by an educational grant from Allergan, Inc.
Spasticity is a common chronic condition estimated to affect over 1 million people in the United States and, unfortunately, is often not adequately recognized or treated. The impact of spasticity can range from minor discomfort, pain, stiffness, sleep disturbance, and bladder dysfunction to complete immobility that, combined with psychological effects, contributes to a significantly impaired quality of life. Careful multidisciplinary assessment is essential in devising a treatment plan that includes physical management strategies, first-line oral therapies, and timely consideration of chemodenervation.
Physiatrists as well other clinicians, residents, and fellows in neurology and physical medicine and rehabilitation who manage patients with spasticity
At the conclusion of this activity, participants should be better able to:
Assess and identify spasticity-related quality-of-life issues in addition to levels of impairment and functional limitations
Discuss and implement treatment strategies that address the individual needs of patients with spasticity
Adopt a multidisciplinary care team approach that integrates nonpharmacologic and pharmacologic strategies in spasticity management
Determine when and how to best administer chemodenervation agents in appropriate patients with spasticity
Conflict Of Interest Disclosure Policy
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, Haymarket Medical Education (HME) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.
Furthermore, HME seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. HME is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
Moderator Michael F. Saulino, MD, PhD Assistant Professor Department of Rehabilitation Medicine Sidney Kimmel Medical College Thomas Jefferson University Philadelphia, PA Physiatrist MossRehab Elkins Park, PA
Dr. Saulino has received consulting fees from SPR Therapeutics and serves on the speakers’ bureaus for Medtronic and Jazz Pharmaceuticals. He has received research funding from Medtronic, Jazz Pharmaceuticals, and Mallinckrodt Pharmaceuticals and is on the board of directors of the North American Neuromodulation Society.
Faculty Katharine E. Alter, MD Clinical Assistant Professor of Pediatrics Physical Medicine & Rehabilitation and Pediatric Rehabilitation Medicine School of Osteopathic Medicine in Arizona A. T. Still University Mesa, AZ Pediatric/Adult Physiatrist Mount Washington Pediatric Hospital Baltimore, MD
Dr. Alter has received speaker’s fees from Allergan, Inc.
David M. Simpson, MD, FAAN Professor of Neurology Director, Clinical Neurophysiology Laboratories Director, Neuromuscular Division Director, NeuroAIDS Program Icahn School of Medicine at Mount Sinai New York, NY
Dr. Simpson has received consulting fees from Allergan, Inc., Merz Pharma, and Ipsen and serves on the speakers’ bureau for Allergan, Inc.
Publishing Staff Disclosures
The HME staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM . Physicians should claim only those credits commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Allergan, Inc., and HME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Allergan, Inc., and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.